Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 140 (TMEM140) is a multi-pass membrane protein encoded by a human gene located on chromosome 7q33. Its expression is notably increased in glioma and certain other cancers, where it promotes cell growth, survival, adhesion, migration, and invasion. TMEM140 knockdown induces cell cycle arrest and apoptosis, primarily through dysregulation of adhesion molecules and apoptotic factors. TMEM140 has also been identified as a host factor that impedes herpes simplex virus-1 replication by interfering with crucial viral protein interactions. While no clinical therapeutics or chemical probes specifically target TMEM140 currently, its role in tumor progression and viral infection points to its potential as both a prognostic biomarker and a therapeutic target in oncology and infectious disease research
For siRNA/knockdown strategies: Antagonism by silencing the gene, which leads to reduced cell proliferation, adhesion, invasion, and increased apoptosis in glioma cells. For viral infection: TMEM140 competitively inhibits the binding of HSV-1 UL31 to UL34, blocking nucleocapsid egress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 140 (TMEM140).